Mendus AB Financials
| IMMU Stock | SEK 8.15 0.03 0.37% |
Mendus |
Understanding current and past Mendus AB Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Mendus AB's financial statements are interrelated, with each one affecting the others. For example, an increase in Mendus AB's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Mendus AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mendus AB. Check Mendus AB's Beneish M Score to see the likelihood of Mendus AB's management manipulating its earnings.
Mendus AB Stock Summary
Mendus AB competes with Hansa Biopharma, Xbrane Biopharma, BioArctic, and Cantargia. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden.| Foreign Associate | USA |
| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0005003654 |
| Business Address | Vstra Trdgrdsgatan 15, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.mendus.com |
| Phone | 46 87 32 84 00 |
| Currency | SEK - Swedish Kronor |
You should never invest in Mendus AB without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Mendus Stock, because this is throwing your money away. Analyzing the key information contained in Mendus AB's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Mendus AB Key Financial Ratios
Mendus AB's financial ratios allow both analysts and investors to convert raw data from Mendus AB's financial statements into concise, actionable information that can be used to evaluate the performance of Mendus AB over time and compare it to other companies across industries.Mendus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mendus AB's current stock value. Our valuation model uses many indicators to compare Mendus AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mendus AB competition to find correlations between indicators driving Mendus AB's intrinsic value. More Info.Mendus AB is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mendus AB's earnings, one of the primary drivers of an investment's value.Mendus AB Systematic Risk
Mendus AB's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mendus AB volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Mendus AB correlated with the market. If Beta is less than 0 Mendus AB generally moves in the opposite direction as compared to the market. If Mendus AB Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mendus AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mendus AB is generally in the same direction as the market. If Beta > 1 Mendus AB moves generally in the same direction as, but more than the movement of the benchmark.
Mendus AB November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mendus AB help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mendus AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mendus AB based on widely used predictive technical indicators. In general, we focus on analyzing Mendus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mendus AB's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.91 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 35.21 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 3.94 |
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.